Amgen's threat surface is not abstract. It's biopharmaceutical intellectual property, global clinical trial data, manufacturing control systems, and supply chain logistics for therapeutics reaching millions of patients. A breach in this environment doesn't mean leaked emails - it means compromised molecular engineering research, disrupted production lines for drugs targeting cardiovascular disease, bone health, inflammation, and oncology, or patient safety events. The attack vectors span IT, OT, and the increasingly blurred lines between them.
Founded in 1980 and headquartered in Thousand Oaks, California, Amgen has operated for over 45 years as one of the world's leading independent biotechnology companies. The scale is significant: global operations, millions of patients served, and a technical stack built on biotechnology and molecular engineering domains. Security here means defending the entire lifecycle - from R&D data integrity to manufacturing systems to the distribution of finished therapeutics.
The company's mission centers on developing innovative human therapeutics to fight serious diseases. That mission creates a specific security mandate: protect the science, protect the systems that make the science scalable, and protect the infrastructure that delivers it. The cybersecurity challenge is protecting a critical healthcare company with decades of operational complexity and global reach.
